等待開盤 12-12 09:30:00 美东时间
0.000
0.00%
Gen Reveals Cybersecurity Predictions for 2026 TEMPE, Ariz., and PRAGUE, Dec. 9, 2025 /PRNewswire/ -- Gen (NASDAQ: GEN), a global leader dedicated to powering Digital Freedom through its fa...
12-09 22:00
New animated YouTube series "The Twelve Days of Scam-mas" makes learning about holiday scams fun, fast and festive TEMPE, Ariz. and PRAGUE, Dec. 1, 2025 /PRNewswire/ -- Avast, a leader in di...
12-01 22:00
TEMPE, Ariz., Nov. 25, 2025 /PRNewswire/ -- GoDaddy (NYSE: GDDY) is packing even more agentic AI power into its recently launched Airo.ai online experience with the addition of six brand-new...
11-25 23:08
Avast takes on sophisticated scams with AI-powered protection for Android and iOS devices TEMPE, Ariz. and PRAGUE, Nov. 12, 2025 /PRNewswire/ -- Avast, a leader in digital security and priva...
11-12 14:00
Norton makes AI-powered scam protection a global standard as convincing scams continue to dominate the threat landscape TEMPE, Ariz. and PRAGUE, Nov. 3, 2025 /PRNewswire/ -- Norton, a leader...
11-03 22:00
Board members include top global executives across multiple functional disciplines TEMPE, Ariz., Oct. 30, 2025 /PRNewswire/ -- Institute for Supply Management® (ISM®) announced its 2025-2026...
10-31 03:39
Top economists provide insights on U.S. recession risks, Arizona growth, and global uncertainties TEMPE, Ariz., Oct. 22, 2025 /PRNewswire/ -- What will 2026 mean for businesses in Arizona an...
10-22 22:23
With 62% of Americans admitting they'd buy a deal on impulse, scammers are betting on shoppers' shortcuts this season. TEMPE, Ariz. and PRAGUE, Oct. 16, 2025 /PRNewswire/ -- Holiday shortcut...
10-16 21:00
Launching October 22, the series unites experts in cybersecurity, policy, and advocacy on the frontlines of identity theft TEMPE, Ariz. and PRAGUE, Oct. 13, 2025 /PRNewswire/ -- Last year ma...
10-13 21:00
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrumPositive results across all three Phase 3 TEMPO trials reinforce the potential of tavapadon, a novel selective dopamine D1/D5 receptor partial agonist, in Parkinson's diseaseIf approved, tavapadon will enhance A
09-26 20:48